Evidence map›Paper›PMID 33560350›Full record

ArticleNeuro-oncology2021

Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

Andrew B Lassman, Timothy F Cloughesy

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  2. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  3. Article
  4. Article
  5. Management of Low-Grade Gliomas.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrew B LassmanDivision of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, New York.
Timothy F CloughesyNeuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Columbia University NCI Community Oncology Research ProgramUG1CA189960 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jennifer E. Amengual, Lisa A. Kachnic · 2014 to 2026
$12.7M
The role of mTORC2 in reprogramming cancer cell metabolismR01NS073831 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MISCHEL, PAUL S · 2011 to 2020
$3.4M
Mammalian models for integrated metabolic and molecular profiling of malignant gliomaR01CA227089 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G, NATHANSON, DAVID A. · 2018 to 2022
$2.7M
Targeting metabolic vulnerabilities in glioblastomaR01CA213133 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NATHANSON, DAVID A. · 2017 to 2021
$2.5M
NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA213133NCI NIH HHS R01 CA227089NCI NIH HHS UG1 CA189960NINDS NIH HHS R01 NS073831
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsOligodendrogliomaDacarbazineHumansTemozolomideDacarbazineTemozolomide

Identifiers

PMID33560350
PMCPMC7992892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.